Athersys’ MultiStem(R) Stem Cell Therapy Receives Orphan Drug Designation in … – NASDAQ
Athersys’ MultiStem(R) Stem Cell Therapy Receives Orphan Drug Designation in …NASDAQThe Company is developing its MultiStem cell therapy as a GvHD prophylaxis in patients undergoing allogeneic hematopoietic stem cell (HSC) transplant and is currently preparing for a Phase II/III clinical study in the area. The MultiStem therapy for …Athersys Treatment for Stem Cell Transplant Complication … Continue reading
